GlassScriptPhysician profile
Helen Dear
NPI 1376998948
$3,980.30
in general payments reported to CMS, 2019-2025
20 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $389 · 2024: $1,665 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $869.55 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $766.02 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $419.46 | 2024-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $353.22 | 2024-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $274.09 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $205.22 | 2023-2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $162.65 | 2024-2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $131.88 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $130.29 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $113.37 | 2023-2024 | Wainua, Farxiga |
| Lilly USA, LLC | $103.48 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $96.93 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $71.17 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $67.35 | 2023-2024 | Xarelto |
| Scpharmaceuticals INC. | $57.49 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $51.23 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $49.34 | 2023 | Arcalyst |
| Pfizer INC. | $24.07 | 2025 | |
| Glaxosmithkline, LLC. | $18.91 | 2025 | Shingrix, Arexvy |
| Kestra Medical Technology Services, INC. | $14.58 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Dear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.